1 completed, 1 withdrawn. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 1, Withdrawn 1 |
Follow Restorbio Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of RTB101 on Illness Associated With Respiratory Tract Infections in the Elderly Dactolisib, Placebo - Clinically Symptomatic Respiratory Illness | Phase 3 | Withdrawn | Restorbio Inc. | 2019-10-21 | 2019-11-22 | |
| A Phase 3 Study to Determine if RTB101 Prevents Clinically Symptomatic Respiratory Illness in the Elderly Dactolisib, Placebo - Respiratory Tract Infections | Phase 3 | Completed | Restorbio Inc. | 1024 | 2019-04-15 | 2021-06-23 |
Respiratory Tract Infections (2) · Hereditary Sensory and Autonomic Neuropathies (1) · Influenza, Human (1) · Pneumonia (1) · Virus Diseases (1)
dactolisib (2)
New Zealand (1)
Dean Quinn, MD (1)